Pfizer's Trading Volume Surges to $13.51 Billion, Ranked 48th Despite Stock Price Decline

On July 15, 2025, Pfizer's trading volume reached $13.51 billion, marking a significant increase of 104.73% compared to the previous day. This surge placed Pfizer at the 48th position in terms of trading volume for the day. However, the stock price of Pfizer (PFE) experienced a decline of 2.92%, marking the third consecutive day of losses, with a total decrease of 4.54% over the past three days.

Pfizer's recent performance has shown mixed results following a 2% intraday drop. The 3-day win rate stands at 47.24%, indicating a moderate level of volatility. The company's oncology sales are expected to face challenges in the second quarter, primarily due to the generic erosion of Ibrance and the ongoing development of the ADC pipeline.

Pfizer's oncology unit is under scrutiny ahead of the second-quarter earnings report. Key drugs within this unit are experiencing both rising demand and competitive pressures, which could impact the company's financial performance. The market capitalization has seen fluctuations, with a notable decrease from session highs, reflecting investor concerns about the future prospects of Pfizer's oncology division.